Peer-reviewedCC BY-NC-NDInternal Medicine
DRESS during chemotherapy with carboplatin, pemetrexed, and osimertinib for lung adenocarcinoma: A case report
Abstract
We report a case of a 40-year-old woman with lung adenocarcinoma who developed a drug reaction with eosinophilia and systemic symptoms (DRESS) during chemotherapy with carboplatin, pemetrexed, and osimertinib. She presented with fever, extensive erythematous rash, and hepatorenal dysfunction (RegiSCAR score = 7). Discontinuation of the offending drugs and supportive care alone led to the complete resolution of the symptoms. She was successfully transitioned to gefitinib without recurrence of symptoms. This case highlights the need for an accurate diagnosis and careful consideration of the indication for corticosteroid therapy in DRESS to ensure timely withdrawal of offending drugs and successful subsequent cancer therapy.
Related
- Third-generation EGFR-TKI plus pemetrexed-platinum chemotherapy versus TKI monotherapy as first-line treatment for EGFR-mutant lung adenocarcinoma with brain parenchymal metastases
- EGFR-mutant lung adenocarcinoma with leptomeningeal metastasis after osimertinib treatment: intrathecal chemotherapy combined with targeted therapy supported by cerebrospinal fluid next generation sequencing — a case report
- Long-term Disease Control After Probable Endobronchial Small-cell Transformation During Osimertinib Therapy for EGFR-mutant Lung Adenocarcinoma
- Amivantamab plus chemotherapy vs. chemotherapy in participants with EGFR-mutant advanced non-small cell lung cancer after progression on osimertinib: a MARIPOSA-2 analysis of the Asian subgroup
- PemToxTrial: An Observational Study of PEMetrexed-Associated Severe HematoTOXicity in Lung Adenocarcinoma with Bone Metastases
BibTeX
@article{okada2026dress,
title = {{DRESS during chemotherapy with carboplatin, pemetrexed, and osimertinib for lung adenocarcinoma: A case report}},
author = {Naoki Okada and Hiroto Takiguchi and Atsushi Ito and Haruka Ikoma and Miyu Yamaoka and Hanami Hirasawa and Hiroki Uotani and Kohei Umemoto and Yukihiro Horio and Naoki Hayama and Yoko Ito and Tsuyoshi Oguma and Koichiro Asano},
journal = {Internal Medicine},
year = {2026},
month = aug,
doi = {10.2169/internalmedicine.6752-25},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_6752-25/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - DRESS during chemotherapy with carboplatin, pemetrexed, and osimertinib for lung adenocarcinoma: A case report
AU - Naoki Okada
AU - Hiroto Takiguchi
AU - Atsushi Ito
AU - Haruka Ikoma
AU - Miyu Yamaoka
AU - Hanami Hirasawa
AU - Hiroki Uotani
AU - Kohei Umemoto
AU - Yukihiro Horio
AU - Naoki Hayama
AU - Yoko Ito
AU - Tsuyoshi Oguma
AU - Koichiro Asano
PY - 2026
DA - 2026/08/08
JO - Internal Medicine
DO - 10.2169/internalmedicine.6752-25
UR - https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_6752-25/_article
AB - We report a case of a 40-year-old woman with lung adenocarcinoma who developed a drug reaction with eosinophilia and systemic symptoms (DRESS) during chemotherapy with carboplatin, pemetrexed, and osimertinib. She presented with fever, extensive erythematous rash, and hepatorenal dysfunction (RegiSCAR score = 7). Discontinuation of the offending drugs and supportive care alone led to the complete resolution of the symptoms. She was successfully transitioned to gefitinib without recurrence of symptoms. This case highlights the need for an accurate diagnosis and careful consideration of the indication for corticosteroid therapy in DRESS to ensure timely withdrawal of offending drugs and successful subsequent cancer therapy.
SN - 1349-7235
SN - 0918-2918
ER -